Beatriz Taveira Constantinou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Beatriz Taveira Constantinou has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Bianca Caroline Benedicto
Universidade Nove de Julho, São Bernardo do Campo São Paulo Brazil
2 shared publications - Jose Arnaldo Shiomi da Cruz
Department of Urology, Federal University of São Paulo Medical School, São Paulo, Brazil
2 shared publications - Amauri Moreira Leite Junior
Universidade Nove de Julho
1 shared publication - Beatriz Brandão da Silva Navas
Universidade Nove de Julho
1 shared publication - Beatriz Sanches Molina
Universidade Nove de Julho
1 shared publication - Breno Cordeiro Porto
Surgical Technique and Experimental Surgery Department, University of São Paulo School of Medicine, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 41
Use of pumpkin seed (Cucurbita pepo) versus placebo and versus alpha-blockers in the management of benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials
Purpose: To compare pumpkin seed (Cucurbita pepo) with placebo and, separately, with alpha-blockers in men with benign prostatic hyperplasia-related lower urinary tract symptoms. Methods: Five databases were searched to 30 April 2025 for randomized controlled trials (RCTs). The primary outcome was change in international prostate symptom score (IPSS), and secondary outcomes included maximum urinary flow (Qmax), prostate volume, prostate-specific antigen (PSA) and adverse events. Each comparator was analyzed separately by random-effects meta-analysis, with RoB 2 for risk of bias. Results: Eight RCTs (2,170 men) were included. Versus placebo, pumpkin seed reduced IPSS at three months (mean difference -0.62, 95% confidence interval [95%CI] -1.15 to -0.09) but not at six months; versus alpha-blockers there was no difference (1.91, IC95% -0.24–4.07). Qmax improved versus placebo only; no other outcome differed from alpha-blockers. Adverse events were fewer with pumpkin seed in one head-to-head trial (odds ratio = 0.21, IC95% 0.07–0.63). Conclusion: Pumpkin seed offers at most a small sub-clinical IPSS benefit over placebo, not maintained at six months, and no significant difference from alpha-blockers. Certainty was low to very low; equivalence is not established.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 41
Open AccessUse of pumpkin seed (Cucurbita pepo) versus placebo and versus alpha-blockers in the management of benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials
Purpose: To compare pumpkin seed (Cucurbita pepo) with placebo and, separately, with alpha-blockers in men with benign prostatic hyperplasia-related lower urinary tract symptoms. Methods: Five databases were searched to 30 April 2025 for randomized controlled trials (RCTs). The primary outcome was change in international prostate symptom score (IPSS), and secondary outcomes included maximum urinary flow (Qmax), prostate volume, prostate-specific antigen (PSA) and adverse events. Each comparator was analyzed separately by random-effects meta-analysis, with RoB 2 for risk of bias. Results: Eight RCTs (2,170 men) were included. Versus placebo, pumpkin seed reduced IPSS at three months (mean difference -0.62, 95% confidence interval [95%CI] -1.15 to -0.09) but not at six months; versus alpha-blockers there was no difference (1.91, IC95% -0.24–4.07). Qmax improved versus placebo only; no other outcome differed from alpha-blockers. Adverse events were fewer with pumpkin seed in one head-to-head trial (odds ratio = 0.21, IC95% 0.07–0.63). Conclusion: Pumpkin seed offers at most a small sub-clinical IPSS benefit over placebo, not maintained at six months, and no significant difference from alpha-blockers. Certainty was low to very low; equivalence is not established.
- Open Access
- 1 May 2025
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 14 (5) , 1261-1272
GreenLight photoselective laser vaporisation versus transurethral resection of the prostate for large prostates: systematic review and meta-analysis
Background: Transurethral resection of the prostate (TURP) stands as a primary surgical intervention for benign prostatic hyperplasia (BPH), although laser techniques, notably photoselective vaporisation of the prostate (PVP), are gaining traction. Previous studies have already assessed the efficacy of TURP and PVP, although with small prostates (Methods: A systematic review was conducted across MEDLINE, Embase, Scopus, Web of Science, and Google Scholar. Studies comparing PVP to TURP in male BPH patients were included. Our primary outcome was the International Prostate Symptom Score (IPSS). Secondary outcomes encompassed maximum urinary flow rate (Qmáx), postvoid residual volume (Vres), operative time, catheterization time, postoperative hospital stay and complications. To assess the risk of bias we used Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for non-randomized studies, and risk of bias 2 tool (Cochrane) (RoB2) for the randomized. Results: Three articles encompassing 159 patients each in the PVP and TURP groups were included. Our analysis revealed no statistically significant difference in IPSS score between PVP and TURP [mean difference (MD) 1.56; 95% confidence interval (CI): 0.52 to 3.64; P=0.14; I2=85%]. TURP demonstrated a reduced operative time (MD 30.35; 95% CI: 11.26 to 49.44; P=0.002; I2=96%), whereas PVP exhibited shorter catheterization time (MD −2.22; 95% CI: −2.44 to −1.99; P2=1%) and postoperative hospital stay (MD −2.20; 95% CI: −2.69 to −1.72; P2=75%). No significant differences were observed in other outcomes assessed. Conclusions: This meta-analysis suggests that PVP is non-inferior to TURP concerning IPSS, Qmáx, Vres, and complications, albeit with a longer operative time. PVP showed a reduced catheterization and postoperative hospital stay.
- 1 May 2025
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 14 (5) , 1261-1272
Open AccessGreenLight photoselective laser vaporisation versus transurethral resection of the prostate for large prostates: systematic review and meta-analysis
Background: Transurethral resection of the prostate (TURP) stands as a primary surgical intervention for benign prostatic hyperplasia (BPH), although laser techniques, notably photoselective vaporisation of the prostate (PVP), are gaining traction. Previous studies have already assessed the efficacy of TURP and PVP, although with small prostates (Methods: A systematic review was conducted across MEDLINE, Embase, Scopus, Web of Science, and Google Scholar. Studies comparing PVP to TURP in male BPH patients were included. Our primary outcome was the International Prostate Symptom Score (IPSS). Secondary outcomes encompassed maximum urinary flow rate (Qmáx), postvoid residual volume (Vres), operative time, catheterization time, postoperative hospital stay and complications. To assess the risk of bias we used Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for non-randomized studies, and risk of bias 2 tool (Cochrane) (RoB2) for the randomized. Results: Three articles encompassing 159 patients each in the PVP and TURP groups were included. Our analysis revealed no statistically significant difference in IPSS score between PVP and TURP [mean difference (MD) 1.56; 95% confidence interval (CI): 0.52 to 3.64; P=0.14; I2=85%]. TURP demonstrated a reduced operative time (MD 30.35; 95% CI: 11.26 to 49.44; P=0.002; I2=96%), whereas PVP exhibited shorter catheterization time (MD −2.22; 95% CI: −2.44 to −1.99; P2=1%) and postoperative hospital stay (MD −2.20; 95% CI: −2.69 to −1.72; P2=75%). No significant differences were observed in other outcomes assessed. Conclusions: This meta-analysis suggests that PVP is non-inferior to TURP concerning IPSS, Qmáx, Vres, and complications, albeit with a longer operative time. PVP showed a reduced catheterization and postoperative hospital stay.